Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Ovarian Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Morgan, R. J., Alvarez, R. D., Armstrong, D. K., Burger, R. A., Castells, M., Chen, L., Copeland, L., Crispens, M. A., Gershenson, D., Gray, H., Hakam, A., Havrilesky, L. J., Johnston, C., Lele, S., Martin, L., Matulonis, U. A., O'Malley, D. M., Penson, R. T., Remmenga, S. W., Sabbatini, P., Santoso, J. T., Schilder, R. J., Schink, J., Teng, N., Werner, T. L., Hughes, M., Dwyer, M. A. 2012; 10 (11): 1339-1349

Abstract

These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

View details for Web of Science ID 000310822900005